Xilio Therapeutics, Inc.
NASDAQ: XLO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Rene Russo
- Employees
- 64
- Headquarters
- Waltham, United States
- IPO year
- 2021
- Market cap
- $59.2M
- Website
- https://www.xiliotx.com
Loading XLO…
Loading profile data…Frequently asked questions about XLO
What does Xilio Therapeutics, Inc. (XLO) do?
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company...
Where does XLO trade?
Xilio Therapeutics, Inc. (XLO) trades on the NASDAQ Global Select.
What sector is XLO in?
Xilio Therapeutics, Inc. (XLO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Xilio Therapeutics, Inc.?
Rene Russo is the chief executive officer of Xilio Therapeutics, Inc. (XLO).
Where is Xilio Therapeutics, Inc. headquartered?
Xilio Therapeutics, Inc. is headquartered in United States.
Does XLO pay a dividend?
Xilio Therapeutics, Inc. (XLO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did XLO go public?
Xilio Therapeutics, Inc. (XLO) completed its initial public offering in 2021.